Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer

NCT01915472 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01915472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01915472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2013
Completion date
August 31, 2015
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer